PrimaBioMed Updates Investors on CANVAS Trial


NY, NY—(7/24/2013) – Matthew Lehman, CEO of Prima BioMed, updated the financial community on the company’s recent progress during an exclusive interview with The Wall Street Analyst.  He discussed the development of personalized immunocellular therapeutics, known as CVac, which uses the body’s own immune system to fight cancer.  Mr. Lehman talked about the CANVAS trial in Germany, trends in the sector, and some of the factors that make the company unique.  He also went over his background, experience, and goals for the upcoming year.


About author

This article was written by The Wall Street Analyzer

The Wall Street Analyzer's staff of writers, analysts, publishers, producers, market researchers, and PR professionals aim to provide investors with the tools they need to make informed decisions on buying stock. Our staff is a mix of financial professionals and media savvy individuals whose experiences bring the best talent from both ends of the spectrum. On one hand our financial experience gives us the ability to identify promising, off the grid companies before they are uncovered by the rest of the market, and on the other hand our media experience allows us to produce interviews which appeal to a large audience because we provide a format in which more investors can understand a featured companies' upside. Our philosophy is to turn stock tickers into stories, ideas into headlines, and technical and financial data into easy to understand tidbits, easier to digest and therefore consumed by a larger audience. These interviews provide a jumping off point for investors to do further research into a prospective company. Our editorials seek to provide an out-of-the-box perspective found in few other financial sites.